CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Sub-Licensee Partner Announces CRO for Phase 1 and Phase 2 Berubicin Trials in Poland
Poland trials will include the first ever Phase 1 trial for pediatric patients suffering from glioblastoma multiforme CNS Pharmaceuticals has made significant strides in its Berubicin manufacturing process due to its dual-track approach and expects to begin production of its drug candidate at Pharmaceuticals International during the third quarter of 2020 The Company’s CFO recently acquired 142,000 shares of common stock in the open market, a move indicative of his confidence in the success of Berubicin clinical trials and its positive impact on the global brain tumor therapeutics market CNS Pharmaceuticals (NASDAQ: CNSP) is moving forward with clinical trials of…
